EXCELYA
6.7.2020 08:02:10 CEST | Business Wire | Press release
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.
Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.
Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them. These investments in innovation and delivery capacity position us to rapidly continue our growth in the short and medium term.”
About Excelya Group
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com .
About Zeincro
Zeincro is a CRO created in 1999 headquartered in the United Kingdom that provides services to more than 20 countries in Central-Eastern & Southern Europe through eight offices. Zeincro provides a full range of services from Phases I to IV with a specialization in clinical operations and safety across most therapeutic areas. With almost 20 years of experience in more than 700 successful clinical studies completed, Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance.
For more information, please visit zeincro.com .
About Koehler eClinical GmbH
Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for its customers. With its strong heritage in biostatistics, it covers all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integration and standardizations. As a specialist in data-centric approaches, the company also operates its proprietary software VITESSA as a combined tool for electronic data capture and clinical trial management. Koehler eClinical GmbH provides full-service support for local and global trials with centralized project management and technology-enabled approaches. It covers the full spectrum of clinical projects, from early to late-phase, including NIS, observational and PASS.
For more information, please visit koehler-eclinical.com .
About The Clinical Company
Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.
For more information, please visit theclinicalcompany.com .
Project Contributors :
- Excelya: François Moisson & Frédéric Paqueville (CEO & Co-Founders), Guillaume Steimer
-
Legal counsel:
- FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
- De Pardieu Brocas Maffei: Philippe Rozec
- Financial Audit: Oderis, Aurélien Vion
- Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer,
- Zeincro: Dr Gregory Sivolapenko,
- Koehler eClinical: Dr Manfred Koehler, Dr Antal Hajos, Michael Pfitzenmaier,
- The Clinical Company: Pim Van de Riet, Chris de Jong, Evert Cuppens, Stijn Valkering, Angélique Kleemans
-
Legal and financial advisors:
- Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
- The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
- Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser
View source version on businesswire.com: https://www.businesswire.com/news/home/20200705005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release
The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo
Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 15:00:00 CET | Press release
A new survey of 130 senior life sciences leaders on AI in pharma R&D and competitive intelligence finds that 92% can name a recent R&D, portfolio, or partnership decision where AI changed the outcome. Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall sh
REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 14:41:00 CET | Press release
All economic indicators have substantially improved:Consolidated turnover of €1,987.9 million (1,819.8 as at 30 September 2025)EBITDA of €354.9 million (335.5 as at 30 September 2025)EBIT of €286.7 million (281.0 as at 30 September 2025)Pre-tax profit of €291.6 million (268.1 as at 30 September 2025)Positive Net Financial Position of €397.0 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to Septembe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
